🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Vivani Medical And 2 Other Stocks Under $5 Insiders Are Buying

Published 04/01/2024, 11:34
Updated 04/01/2024, 12:40
© Reuters.  Vivani Medical And 2 Other Stocks Under $5 Insiders Are Buying
VANI
-
CUROQ
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

The Dow Jones index closed lower by around 285 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Vivani Medical

  • The Trade: Vivani Medical, Inc. (NASDAQ: VANI) Director Gregg Williams acquired a total of 7,111 shares an average price of $1.01. To acquire these shares, it cost around $7,182.
  • What’s Happening: Vivani Medical, during November, posted a wider-than-expected quarterly loss.
  • What Vivani Medical Does: Vivani Medical Inc is a preclinical stage biopharmaceutical company.
Harvard Apparatus Regenerative Technology
  • The Trade: Harvard Apparatus Regenerative Technology Inc. (OTC: HRGN) CEO Junli He acquired a total of 2,700 shares at at an average price of $4.76. To acquire these shares, it cost around $12,852.
  • What’s Happening: Harvard Apparatus Regenerative Technology announced that it officially executed a sponsored research agreement with Drs. Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.
  • What Harvard Apparatus Regenerative Technology Does: Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects.
Check This Out: Top 3 Industrials Stocks That Could Blast Off In Q1

CURO Group

  • The Trade: CURO Group Holdings Corp. (NYSE: CURO) CEO Douglas Clark acquired a total of 10,000 shares at an average price of $0.85. The insider spent around $8,479 to buy those shares.
  • What’s Happening: CURO Group Holdings, during November, posted weak quarterly results.
  • What CURO Group Does: CURO Group Holdings Corp is a consumer finance company serving a full spectrum of non-prime, near-prime and prime consumers in portions of the U.S. and Canada.

Don’t forget to check out our premarket coverage here

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.